Mesterolon
proviron · mesterolon · MESTERELONE · testiwop · masterolone · sh723 · NSC-7504 · NSC 75054

Identifikatoren & physikalische Daten
| CAS No. | 1424-00-6 |
|---|---|
| Summenformel | C20H32O2 |
| Durchschnittliche Molmasse | 304,5 g/mol |
| Monoisotopische Masse | 304,24023026 g/mol |
| SMILES | C[C@H]1CC(=O)C[C@@H]2CC[C@H]3[C@@H]4CC[C@H](O)[C@@]4(C)CC[C@@H]3[C@]21C |
| InChIKey | UXYRZJKIQKRJCF-TZPFWLJSSA-N |
| PubChem CID | 15020 |
| ChEMBL | CHEMBL258918 |
| ChEBI | CHEBI:135293 |
| EC No. | 215-836-3 |
| DTXSID | DTXSID90878533 |
| Lokaler Name | Mesterolon |
Chemische & physikalische Eigenschaften
| XLogP | 4,1 |
|---|---|
| Polarare Oberfläche (TPSA) | 37,3 |
| H-Brücken-Donoren | 1 |
| H-Brücken-Akzeptoren | 2 |
| Frei drehbare Bindungen | 0 |
| Schwere Atome | 22 |
| Formalladung | 0 |
| Komplexität | 486 |
| Schmelzpunkt | 204 °C208 °C |
| Physical Description | Solid |
| Siedepunkt | 420.3±45.0 °C(Predicted) |
| Dichte | 1.156 g/cm3 |
| Brechungsindex | 17.6 ° (C=0.9, CHCl3) |
| Lagerbedingungen | 2-8°C |
| Löslichkeit | Practically insoluble in water, sparingly soluble in acetone, in ethyl acetate and in methanol3mg/L at 20℃ |
| pKa (Säurekonstante) | 15.09±0.70(Predicted) |
| Merck | 5916 |
| Hauptanwendungen | forensics and toxicologypharmaceutical (small molecule)veterinary |
| InChI | InChI=1/C20H32O2/c1-12-10-14(21)11-13-4-5-15-16-6-7-18(22)19(16,2)9-8-17(15)20(12,13)3/h12-13,15-18,22H,4-11H2,1-3H3/t12-,13-,15-,16-,17-,18-,19-,20-/s3 |
| InChIKey | UXYRZJKIQKRJCF-TZPFWLJSSA-N |
| SMILES | [C@@]12([H])CC[C@@]3([H])CC(=O)C[C@H](C)[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@H](CC[C@@]21[H])O |&1:0,4,10,12,14,18,20,23,r| |
| CAS Datenbank | 1424-00-6(CAS DataBase Reference) |
Sicherheit & Vorschriften
| GHS-Einstufung | WarningH302 (97.5%): Harmful if swallowed [Warning Acute toxicity, oral]H312 (97.5%): Harmful in contact with skin [Warning Acute toxicity, dermal]H332 (97.5%): Harmful if inhaled [Warning Acute toxicity, inhalation]P261, P264, P270, P271, P280, P301+P317, P302+P352, P304+P340, P317, P321, P330, P362+P364, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 40 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. |
|---|---|
| Regulatorische Informationen | DEA schedule III controlled substanceStatus: Active Update: 30-03-2020 https://echa.europa.eu/registration-dossier/-/registered-dossier/12497 |
| Hazard Classes and Categories | Acute Tox. 4 (97.5%) |
| Wassergefährdungsklasse (WGK) | 3 |
| Zollcode | 29372900 |
| RTECS-Nr. | BV8063400 |
| R-Sätze (R) | 20/21/22-38-19-11-61-60 |
| Gefahrensymbole | Xn,T,F |
| Sicherheitshinweise (S) | 22-24/25-36/37/39-45-53 |
| Lagerklasse | 6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects |
| Gefahrenklasse | Aquatic Chronic 2Carc. 2Lact.Repr. 1B |
| DEA Controlled Substances | CSCN: 4000CSA SCH: Schedule IIINARC: No |
Anwendungen & Verwendung
Beschreibung
Mesterolone (Item No. 21171) is an analytical reference standard categorized as an anabolic androgenic steroid. Formulations containing mesterolone have been used in patients with low testosterone or symptoms of aging male syndrome. Mesterolone cannot be aromatized to estrogens, unlike other androgens. This compound is the active ingredient in different pharmaceutical preparations that have been used medically but have also been widely applied in sports in order to improve athlete performance. Mesterolone is regulated as a Schedule III drug in the United States. This product is intended for research and forensic applications.
Verwenden
Mesterolone is a synthetic androgen and a dihydrotestosterone derivative. Mesterolone is rarely used for replacement therapies due to its weak androgenic activity.